Human | NEWENTRY | 192343 | Record to support submission of GeneRIFs for a gene not in Gene (human; man). | definitive evidence that eIF6 and dicer are both upregulated in a significant proportion of ovarian serous carcinomas |
Human | C19orf6 | 91304 | | Study provides first characterization of human membralin and suggests that membralin is a novel tumor-associated marker in ovarian serous carcinomas |
Human | MSLN | 10232 | mesothelin | Among 150 carcinomas of multiple anatomic sites, we found the highest average expression of MSLN in serous carcinomas of the ovary and adenocarcinomas of the pancreas, consistent with previous reports, as well as measurable but less-striking expression in pulmonary, gastric/esophageal, and colorectal adenocarcinomas. The mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma |
Human | FRAT1 | 10023 | frequently rearranged in advanced T-cell lymphomas | findings support that Wnt/beta-catenin signalling may be aberrantly activated through FRAT1 overexpression in ovarian serous adenocarcinomas |
Human | BARX2 | 8538 | BARX homeobox 2 | We have previously shown that BARX2 expression is low in clear cell/endometrioid and high in serous adenocarcinomas of the ovary, histologic variants that are less and more sensitive, respectively to platinum chemotherapy. |
Human | LEFTY2 | 7044 | left-right determination factor 2 | However, some serous adenocarcinomas of the ovary also exhibited TGFB4 (ebaf) mRNA. |
Human | MAP2K4 | 6416 | mitogen-activated protein kinase kinase 4 | Homozygous deletion or reduced expression of MKK4 may contribute to the development of ovarian serous carcinoma |
Human | SDC1 | 6382 | syndecan 1 | In summary, ovarian carcinomas exhibit up-regulated expression of several extracellular matrix proteins, and syndecan 1 represents a novel tumor-associated marker in ovarian serous carcinomas |
Human | PAX2 | 5076 | paired box 2 | PAX2 was identified in ovarian papillary serous carcinoma cells derived from Mullerian epithelium or surrounding ovary |
Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | Using an immunocytochemical assay with a specific anti-nm23 polyclonal antibody, nm23 expression was evaluated in ascitic effusions of 45 patients with ovarian serous adenocarcinoma and ascites in normal and/or hyperplastic mesothelial cells from 37 women with various neoplasms (12 ovarian neoplasms) free of malignant cells as controls. |
Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | Poorly differentiated ovarian serous carcinomas express higher levels of Ki67, BM28, EGFR, and c-erbB-2 proteins. |
Human | KRAS | 3845 | Kirsten rat sarcoma viral oncogene homolog | results demonstrate that the mutational status of BRAF and KRAS is distinctly different among histologic types of ovarian serous carcinoma, occurring most frequently in invasive micropapillary serous carcinomas and its precursors, serous borderline tumors |
Human | IGFBP5 | 3488 | insulin-like growth factor binding protein 5 | We concluded that IGFBP2 and IGFBP5 might play a role in the development of high-grade ovarian serous carcinoma, but not in mucinous or clear cell ovarian carcinomas. |
Human | HLA-G | 3135 | | RESULTS: On the basis of immunohistochemistry, 45 (61%) of 74 ovarian serous carcinomas and 22 (25%) invasive ductal carcinomas of the breast demonstrated HLA-G immunoreactivity ranging from 2 to 100% of the tumor cells. |
Human | GCLM | 2730 | glutamate-cysteine ligase, modifier subunit | (1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance. |
Human | GCLC | 2729 | glutamate-cysteine ligase, catalytic subunit | (1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance. |
Human | ETV4 | 2118 | ets variant 4 | In conclusion, PEA3 is expressed at all anatomic sites in serous ovarian cancer and co-localizes with Erg, Ets-2 and several metastasis-associated molecules. |
Human | ETS2 | 2114 | v-ets avian erythroblastosis virus E26 oncogene homolog 2 | In conclusion, PEA3 is expressed at all anatomic sites in serous ovarian cancer and co-localizes with Erg, Ets-2 and several metastasis-associated molecules. |
Human | CLDN3 | 1365 | claudin 3 | CLDN3 overexpression can be used as a prognostic indicator in ovarian serous carcinomas and it may be a promising target for antibody-based therapy of ovarian carcinomas |
Human | CD44 | 960 | CD44 molecule (Indian blood group) | results suggest that CD44S and CD44v5 are differentially expressed in early and advanced ovarian serous carcinomas and support previous studies that suggest a role for CD44 and stromal hyaluronic acid in the dissemination of ovarian epithelial cancer |
Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | results demonstrate that the mutational status of BRAF and KRAS is distinctly different among histologic types of ovarian serous carcinoma, occurring most frequently in invasive micropapillary serous carcinomas and its precursors, serous borderline tumors BRAF gene plays a "gatekeeper" role but does not act as a predisposition gene in the development of low-grade ovarian serous carcinomas Activation of MAPK is regulated by upstream kinases including KRAS and BRAF, which are frequently mutated in low-grade ovarian serous carcinoma. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways. |
Human | AKT2 | 208 | v-akt murine thymoma viral oncogene homolog 2 | In this study, we analyzed the sequence mutations in PIK3CA and AKT2 genes using purified tumor cells that were isolated from high-grade ovarian serous carcinomas and serous borderline tumors (SBTs) and assessed gene amplification using a dual-color FISH on tissue microarrays. |
Human | PARP1 | 142 | poly (ADP-ribose) polymerase 1 | This study indicates that PARP expression is frequently upregulated in ovarian serous carcinomas, related with MIB-1 LIs and p53 expression, and may serve as a marker of aggressive behavior with prognostic value |